Endocrine Abstracts

Lung carcinoids are slow-proliferating neuroendocrine neoplasms commonly showing low mutational burden but a high heterogeneity and difficult clinical management. Despite valuable advances in their molecular characterization, some aspects remain still unknown. Recent studies have shown that alternative splicing is severely dysregulated in lung carcinoids, where it could promote tumoral features. In contrast, the role of some molecular systems closely related to splicing and ot...

Lung neuroendocrine neoplasms (LungNENs) are highly heterogeneous tumors, which are classified by the WHO according to their histological grade into low grade: Typical Carcinoids (TC) and intermediate grade Atypical Carcinoids (AC), and high-grade: Large Cell Neuroendocrine Carcinoma (LCNEC) and Small Cell Lung Cancer (SCLC). Recently, a number of studies have tried to untangle the molecular features that define each subtype by applying different approaches, including genomic,...

Lung neuroendocrine neoplasms (LungNENs) comprise a diverse group of rare tumors with a commonly difficult and late diagnosis, which often require complex management and treatment. The most frequently mutated genes in LungNENs have recently been identified, including known components of the chromatin-regulating pathways such as MEN1, PSIP1 and ARID1A, which are the subject of ongoing detailed studies. In contrast, other key regulatory mechanisms, par...

Introduction: Emerging evidence indicates that dysregulation of alternative splicing represents a new hallmark of cancer. This dysregulation may arise from mutations or altered expression of specific components of the splicing machinery. To date, splicing machinery status has not been studied in lung neuroendocrine neoplasms: typical and atypical pulmonary carcinoids.Objectives: Here, we aimed to analyzing the splicing machinery in pulmonary carcinoids a...

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...